Tauriga Sciences Inc. Confirms Substantial Pre-Orders for its 25mg CBD & CBG Infused Tauri-Gum
Tauriga Sciences, Inc. (TAUG) announces significant pre-orders for its new 25mg CBD & CBG infused Tauri-Gum™ products, including flavors like Mint and Blood Orange. The company has successfully reduced production costs, ensuring no increase in retail prices. Strong e-commerce sales in the first half of April 2021 bolster confidence in growth prospects for FY 2022. Additionally, Tauriga is advancing its pharmaceutical initiative for a nausea-regulation product aimed at chemotherapy patients, highlighted by a recent patent application conversion.
- Substantial pre-orders for 25mg CBD & CBG Tauri-Gum™.
- No increase in retail prices despite enhanced product concentration.
- Strong e-commerce sales indicate growing demand.
- Advancement in pharmaceutical development for nausea regulation.
- None.
NEW YORK, NY, April 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has received substantial Pre-Orders for its new, 25mg CBD & CBG infused Tauri-Gum™ versions. The enhanced 25mg CBD & CBG infusion concentrations apply to five distinct Tauri-Gum™ SKUs: Mint (CBD), Blood Orange (CBD), Pomegranate (CBD), Peach-Lemon (CBG), and Black Currant (CBG).
CBD = CANNABIDIOL
CBG = CANNABIGEROL
The Company has made the following strategic decision: There will be No Increase in Tauri-Gum™ Retail Prices (“MSRP”). The Company has been successful in reducing costs (basic factors of production costs), pursuant to the Tauri-Gum™ manufacturing process.
Lastly, the Company has generated strong E-Commerce sales during the first two weeks of April 2021. Between the Pre-Orders (25mg Tauri-Gum™) and its strong E-Commerce sales, the Company is confident in its growth prospects for Fiscal Year 2022 (Period: April 1, 2021 – March 31, 2022).
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Attachment
FAQ
What are the new products launched by Tauriga Sciences (TAUG) in April 2021?
What is the significance of the pre-orders announced by Tauriga Sciences (TAUG)?
How has Tauriga Sciences (TAUG) managed its retail pricing for Tauri-Gum™?
What are Tauriga Sciences' growth prospects for Fiscal Year 2022?
What pharmaceutical initiative is Tauriga Sciences (TAUG) pursuing?
